# CR-001

Source: https://onco.cc/drugs/cr-001/  
OnCo record `cr-001` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CR-001 is an experimental tetravalent bispecific antibody from Crescent Biopharma, in phase 2 trials for non-small cell lung cancer and advanced solid tumours.

## Summary

CR-001 (SKB118) is a tetravalent bispecific antibody from Crescent Biopharma, with Sichuan Kelun-Biotech Biopharmaceutical as licensee (Greater China). A tetravalent bispecific antibody that blocks PD-1 and VEGF together; the company says it was designed to show the same cooperative pharmacology as ivonescimab, with PD-1 binding increased in the presence of VEGF. Its furthest stage is phase 2, for non-small cell lung cancer and advanced solid tumours. ClinicalTrials.gov registers it in 4 studies linked below. Global (ex-Greater China) phase 1/2 ASCEND trial recruiting; Kelun-Biotech runs phase 2 combination trials with sacituzumab tirumotecan in China under the name SKB118. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: SKB118
- Tags: pipeline; ctgov-ingest
- Code: CR-001
- Modality: Tetravalent bispecific antibody
- Mechanism: A tetravalent bispecific antibody that blocks PD-1 and VEGF together; the company says it was designed to show the same cooperative pharmacology as ivonescimab, with PD-1 binding increased in the presence of VEGF.

## Sources

- Crescent Biopharma: crescentbiopharma.com: https://www.crescentbiopharma.com/pipeline
- Crescent Biopharma: crescentbiopharma.com: https://www.crescentbiopharma.com/pipeline
- Crescent Biopharma: crescentbiopharma.com: https://www.crescentbiopharma.com/pipeline
- Crescent Biopharma: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07586943
- ClinicalTrials.gov: trials of CR-001: https://clinicaltrials.gov/search?intr=CR-001

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [Crescent Biopharma](https://onco.cc/companies/crescent-biopharma/), [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)
- trials: [A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure](https://onco.cc/trials/nct07854509/), [CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07335497/), [SKB118 Injection in Advanced Solid Tumors](https://onco.cc/trials/nct07586943/), [SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07697586/)

---
JSON: https://onco.cc/api/v1/entities/cr-001.json